Fiocruz

Brazil's Fiocruz, through its Farmanguinhos unit, has begun fully domestic production of tacrolimus, an immunosuppressant to prevent organ transplant rejection. The milestone stems from a Product Development Partnership (PDP) with Brazilian firm Libbs, which acquired manufacturing technology from India's Biocon. Farmanguinhos now becomes the sole supplier to the SUS public health system.

January 21, 2026 由 AI 报道

Pharmaceutical company Gilead Sciences has signed a memorandum of understanding with Farmanguinhos, part of Fiocruz, to assess technology transfer and local production of lenacapavir, a semestral HIV prevention injection. The deal aims to lower costs and improve accessibility in Brazil, though it is not yet a formal commitment. Anvisa approved the drug on January 12, 2026.